And by developing its own PD-1 drug the German company hopes to avoid ... Merck to develop combinations with marketed checkpoint inhibitors such Opdivo and Keytruda. Of course the risk is that ...

If approved, serplulimab would be the first PD-1 inhibitor for ES-SCLC, said Henlius, although the drug would launch into a category in which PD-L1 inhibitors from AstraZeneca and Roche are ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway are widely used in cancer immunotherapy, but poor tissue distribution or immune-related adverse events often limit their application. New ...

Scientists are learning how cancer cells outwit cutting-edge cancer therapies like checkpoint inhibitors—and developing ...

Researchers from Zhejiang Jieyuan Med-Tech Co. Ltd. and collaborators have reported the design and preclinical characterization of a novel series of benzylamine derivatives acting as PD-1/PD-L1 ...

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

"The strains in our lead drug candidate, KAN-001 ... improve outcomes for cancer patients who have been resistant to immune checkpoint inhibitors (ICIs) like anti-PD-1. With this trial data, Kanvas ...

The test improved prediction of patient benefit from anti-PD-1 immune checkpoint inhibitors (ICIs) as a monotherapy and with ...

However, despite their promise, checkpoint inhibitor therapies tend to work ... including tumors subjected to PD-1-blocking ...